AbCellera Biologics Inc.
AbCellera Biologics Inc.
Your view on ABCL
Overview
What the company does, where it operates, and who runs it.
About AbCellera Biologics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Carl L.G. Hansen
- Headquarters
- 2215 Yukon Street, Vancouver, BC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Carl L.G. Hansen
- Headquarters
- 2215 Yukon Street, Vancouver, BC, CA
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs.
As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for AbCellera Biologics Inc. from FRC's valuation model, read against the market price. ABCL last traded at $11.95; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for AbCellera Biologics Inc.. Starting points for AbCellera Biologics Inc.: EPS -$0.47, beta 1.19 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for AbCellera Biologics Inc.. AbCellera Biologics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for AbCellera Biologics Inc.. Trailing twelve-month EPS for AbCellera Biologics Inc. stands at -$0.47. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$9.00
Median
$18.00
High
$30.00
Average target · 1 new target in the last month, average $21.00
Analyst Ratings
- Strong Buy0
- Buy12
- Hold1
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.21 | -$0.13 | -$0.63 | -$0.66 |
| Low estimate | -$0.25 | -$0.17 | -$0.66 | -$0.69 |
| High estimate | -$0.17 | -$0.09 | -$0.59 | -$0.58 |
| No. of analysts | 3 | 2 | 4 | 6 |
| Year-ago EPS | -$0.03 | -$0.14 | -$0.49 | — |
| Growth | -603.7% | +9.9% | -27.6% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $7.47M | $8.88M | $29.18M | $32.97M |
| Low estimate | $3.73M | $4.67M | $22.44M | $11.82M |
| High estimate | $9.18M | $13.09M | $32.57M | $53.40M |
| No. of analysts | 6 | 3 | 9 | 9 |
| Year-ago revenue | $44.85M | $8.31M | $75.13M | — |
| Growth | -83.3% | +6.8% | -61.2% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for AbCellera Biologics Inc.. AbCellera Biologics Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
AbCellera Biologics Inc. valued side by side against its closest peers. AbCellera Biologics Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold AbCellera Biologics Inc., and how their positions are changing. At a $3.90B market value, institutional positions materially move AbCellera Biologics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by AbCellera Biologics Inc. executives and directors. Shares of AbCellera Biologics Inc. have traded between $1.89 and $6.51 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for AbCellera Biologics Inc.. Coverage tracks AbCellera Biologics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of AbCellera Biologics Inc.